USFDA Gives Final Approval to Aurobindo Pharma for Manufacturing Sevelamer Carbonate Oral suspension
DSIJ Intelligence / 15 Jun 2017
Aurobindo Pharma Limited is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
The US Food & Drug Administration (U.S. FDA) gave its final approval to Aurobindo Pharma to manufacture Sevelamer Carbonate Oral suspension, 0.8 gm and 2.4 gm, the company informed the bourses on Thursday.
Aurobindo Pharma Limited is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
Sevelamer Carbonate oral suspension is prescribed for the control of serum phosphorus in patients with chronic kidney disease.
Meanwhile, at Rs 638.55 per share at 1128 hours IST on BSE, the stock was trading higher by 6.1%. It hit a high of Rs 640.80 and a low of Rs 600.75 so far during the day. The stock has under performed BSE Sensex and BSE Healthcare index over a period of one year.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.